Navigation Links
Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
Date:6/16/2008

was a phase II study of Schering Plough's CCR5 antagonist, vicriviroc, in highly treatment experienced HIV patients. This new analysis compared treatment outcomes based on the prospective selection of patients with R5 tropic virus by the original Trofile test versus treatment outcomes based on the re-classification using the enhanced version of the assay.

The ACTG 5211 study enrolled subjects who had R5 virus at screening as determined by the original Trofile assay. The analysis reported at this week's workshop demonstrated that recent enhancements to Trofile enable the assay to further optimize patient selection for CCR5 antagonist treatment by successfully identifying patients that experienced reduced virologic response to vicriviroc. In the patients originally identified as R5 tropic, based on test results obtained with the newly enhanced sensitivity of Trofile, greater reductions in viral load were observed in vicriviroc recipients confirmed to have pure R5 virus populations (1.95 log reduction at week 24) compared to those newly re-classified as having minor subpopulations of CXCR4-using virus (0.57 log reduction at week 24) (P<0.001).

Additional work described at the meeting focused on the use of Monogram's phenotypic and genotypic technology to identify specific markers of HIV resistance to new drug targets/classes. Monogram has assays in advanced development that accurately assess resistance to CCR5 antagonists such as maraviroc (Selzentry, Pfizer) and vicriviroc (Schering-Plough), and integrase inhibitors such as raltegravir (Isentress, Merck) and elvitegravir (Gilead Sciences).

Trofile, incorporating sensitivity enhancements, together with PhenoSense(TM), PhenoSenseGT(TM) and GeneSeq(TM) HIV drug resistance assays constitute Monogram's portfolio of assays for the optimization of antiretroviral therapy for HIV infection. Determining a patient's HIV profile at the molecular and phenotypic level, and the effect of therapy on that profile
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
2. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
3. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
4. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
5. Olympus FluoroPoint(TM) System Provides High-Sensitivity Single Molecule and Protein Interaction Analysis for Screening and Research
6. Study Reaffirms Superiority of Trofile(TM) Assay
7. New York Medicaid Program Establishes Coverage for Trofile(TM)
8. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
9. ProImmune Launches New MHC-Peptide Binding Assay for Class II HLA Alleles
10. Assay Designs(TM) Announces Additions to the Leadership Team
11. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... FL (PRWEB) May 26, 2015 ... Inc. have announced plans for the company’s first cellular ... 2015, followed by a full day, hands-on stem cell ... by J. Victor Garcia Gimenez, M.D., President of Therapeutic ... the medical community’s increasing interest in regenerative medicine and ...
(Date:5/26/2015)...  A simple blood test developed at the University ... Alzheimer,s disease is a step closer to being used ... that are needed before a blood test could be ... & Dementia . The guidelines establish protocols and reflect ... includes UNT Health Science Center. "If we ...
(Date:5/26/2015)... mája 2015 Kevin Xu , ... prezidentom Barackovi Obamovi a Billovi Clintonovi za ich ... Dr. Rongxiang Xu , otca Kevina. ... Dr. Xu bol pionier, inovátor, humanitárny pracovník ... v oblasti vedy a príkladné vedenie svojej komunity ...
(Date:5/26/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... company,s Phase IIb trial of ORMD-0801, its oral insulin ... The submission was made under the company,s existing Investigational ... study of ORMD-0801 for type 2 diabetics is designed ...
Breaking Biology Technology:Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3Guidelines bring UNT Health Science Center's blood test for Alzheimer's one step closer 2Dr. Rongxiang Xu, O legende 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3
... the leading online,information source for life science ... launched the 2nd Edition of the Southern ... science community of the Southeastern,United States. The ... that constitute the dynamic biopharmaceutical industry in ...
... Celgosivir 4-Week Viral Kinetics Study Data on ... Monday December 3, ... Inc.,(TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious,diseases, ... at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results ...
... NOLabs AB, the Swedish,medtech company developing innovative ... Technology, today reported that it has,achieved another ... new line of,products for wounds infected by ... a bacterium that is particularly,troublesome in hospital-acquired ...
Cached Biology Technology:BioSpace Launches 2nd Edition of Southern Pharm(TM) Hotbed Campaign 2MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification 2NOLabs AB Achieves Break-Through in Fight Against MRSA-Bacteria 2
(Date:5/21/2015)... May 21, 2015 According ... Market by Solutions (Hardware, Software, Services), by Applications (Surveillance ... others), by End-Users (Military & Defense & Commercial) ... Thermal Imaging Market is expected to grow from ... 2020, at a Compound Annual Growth Rate (CAGR) ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. ... that its wholly owned subsidiary, 3D-ID LLC, a company ... Team Battelle for the biometrics technology portion of the ... Contract from the Department of the Army. ... products developed for government, law enforcement and security agencies. ...
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... stem cell research journals? This question has been ... Department of Neurosurgery and Brain Repair at the University of ... Stem Cell Reviews and Reports . Both Sanberg ... being published in the proliferating stem cell journals. ...
... herd of cattle is more than just cows. It,s a ... and hedge against drought. For many smallholder farmers, the loss ... Yet a grievous number of cattle in sub-Saharan Africa ... $40 billion, some twenty-five percent of the total value of ...
... Spring Harbor, NY -- One of the most tantalizing developments ... of targeted treatments, which have proven highly effective in holding ... for a limited period of time. A team led ... Harbor Laboratory (CSHL), today published results of a study that ...
Cached Biology News:Cow vaccines go vroom 2Cow vaccines go vroom 3New mechanisms of tumor resistance to targeted therapy in lung cancer are discovered 2
Anti-NeuroD 6 Immunogen: Synthetic peptide. Available Date: 36708...
HOXC11 Antibody...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Biology Products: